Date: December 16, 2021

Location: Fujian Cancer Hospital

▍Developing Organoids, Benefiting the Country

As an irreplaceable model in the era of precision medicine, organoids have become a key research focus for many hospitals. bioGenous was invited to hold the "Developing Organoids, Benefiting the Country" event——an academic symposium on "Organoid Technology and Translation" at Fujian Cancer Hospital.

During the event, bioGenous technical team conducted a live intrahepatic cholangiocarcinoma organoid culture experiment in the hospital’s laboratory. bioGenous’ full-process tumor organoid culture kit provided comprehensive support, from clinical sample collection to tissue processing and digestion, tumor stem cell cluster extraction, and 3D culture, efficiently and rapidly achieving successful organoid culture.

▍Symposium on "Organoid Technology and Translation"

During the event, Secretary LIU Jingfeng from Fujian Cancer Hospital delivered a speech. Following this, bioGenous Chief Scientist, Professor Zhao Bing from Fudan University, presented a report titled "Human Organoids Growth Simulation and Disease," and bioGenous CTO, Dr. NI Chao, delivered a report on "Applications of Organoids in Drug Development and Clinical Translation."

 Secretary LIU Jingfeng delivered a speech

 Professor ZHAO Bing: Human Organoid Growth Simulation and Disease

 倪超Dr NI Chao——Application of Organoids in Drug Development and Clinical Translation

Edit | bioGenous Content Team

Pictures | water

Fujian Cancer Hospital began its construction in 1979, admitted its first patients in 1984, and officially opened in 1986. The Fujian Cancer Prevention and Treatment Office is affiliated with the hospital. In 1997, it was rated as a Class A Tertiary Cancer Hospital by the Ministry of Health. In 2001, the Fujian Cancer Research Institute was established and merged with the hospital. In 2013, the hospital was listed as a National Key Clinical Specialty Unit for Oncology, and in 2016, it became affiliated with Fujian Medical University as the Fujian Medical University Cancer Hospital. In 2017, it was designated as a high-level cancer medical center construction unit in Fujian Province. In 2020, it was selected as a candidate for the National Regional Cancer Medical Center.

As a key platform for cancer prevention, treatment, and research in Fujian, the hospital has developed into a leader in oncology technology, disciplines, talent, and services. It has established distinct advantages in cancer prevention, control, and comprehensive treatment, playing a leading role in the province and surrounding regions. The hospital has formed a comprehensive oncology hub, integrating National Key Clinical Specialties, a National Drug Clinical Trial Institution, the Fujian Provincial Key Laboratory of Cancer Translational Medicine, the Fujian Provincial Key Laboratory of Cancer Biotherapy, the Fujian Provincial Institute of Oncology Precision Medicine, the Fujian Provincial Engineering Research Center for Cancer Precision Diagnosis and Immunotherapy, the Fujian Provincial Clinical Medicine Research Center for Radiation and Immunotherapy, and the Fujian Provincial Clinical Medicine Research Center for Hepatobiliary and Pancreatic Tumors.